GE to sell biopharma biz for $21B, postpone healthcare IPO

General Electric Company (GE) is selling its biopharma business to Danaher for $21.4 billion, the company announced Feb. 25. With a definitive agreement signed between the two parties, GE’s previous plan to spin off its healthcare sector with its own initial public offering is likely put on hold, GE Chairman and CEO Larry Culp told CNBC.

GE previously filed confidential paperwork for an IPO for its healthcare unit at the end of 2018. The offering was originally expected to take place in 2019. Danaher is a global science and technology entity with more than 20 operating companies and 71,000 associates.

"An IPO [for GE Healthcare] in 2019 looks unlikely at this point," Culp told CNBC.

GE Biopharma provides instruments, consumables and software to support the research, discovery, process development and manufacturing workflows of biopharmaceutical drugs. The business is expected to generate $3.2 billion in 2019. The acquisition by Danaher is expected to be completed in the fourth quarter of 2019.

“We expect GE Biopharma to advance our growth and innovation strategy in an important and highly attractive life science market,” Danaher President and CEO Thomas Joyce, Jr. said in a statement. “We see meaningful opportunities to harness the power of the Danaher Business System to further provide GE Biopharma's customers with end-to-end bioprocessing solutions that help enable breakthrough development and production capabilities.”

The change in plans for GE doesn’t mean the IPO for the healthcare segment is completely off the table. GE Healthcare accounted for almost 16 percent of the company’s total sales and more than 40 percent of its operating profit in 2017, about $19 billion in revenue, CNBC reported. The intent to spin off the healthcare unit was to allow GE to focus on its core industry and energy businesses.

Upon news of the biopharma deal, GE shares surged nearly 8 percent by end-of-day trading Monday.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”